Drug Trial Radar · NCT02661503
HD21 for Advanced Stages
Last checked: Nov 20, 2026Latest source record: May 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,500
Actual
Start
Jul 2016
Primary completion
Dec 2022
Study completion Sep 2025
Sponsor
- Lead sponsor
- University of CologneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 22, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary objective of the trial is to demonstrate non-inferior efficacy of six cycles of BrECADD compared to six cycles of escalated BEACOPP, each followed by radiotherapy to PET-positive residual lesions ≥2.5 cm, in terms of progression free survival (efficacy objective). If non-inferior efficacy can be shown, the co-primary objective is to further demonstrate reduced toxicity of the BrECADD treatment compared to the escalated BEACOPP treatment measured by treatment related morbidity (TRMorbidity objective).
Conditions
- Classical Hodgkin Lymphoma
Interventions
BleomycinDrug
EtoposideDrug
DoxorubicinDrug
CyclophosphamideDrug
VincristineDrug
ProcarbazineDrug
PrednisoneDrug
Brentuximab VedotinDrug
DacarbazineDrug
DexamethasoneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: 5 years
- Treatment Related MorbidityTime frame: during 6 cycles of chemotherapy (21-day cycles)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital of Cologne
Cologne, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.